Human Monoclonal Antibodies as Candidate Therapeutics Against Emerging Viruses and HIV-1

被引：0
作者：
Zhongyu Zhu [1 ]
Ponraj Prabakaran [1 ,2 ]
Weizao Chen [1 ]
Christopher CBroder [3 ]
Rui Gong [4 ]
Dimiter SDimitrov [1 ]
机构：
[1] Protein Interactions Group, National Cancer Institute, National Institutes of Health
[2] Basic Research Program, Science Applications International Corporation-Frederick, Inc
[3] Department of Microbiology and Immunology, Uniformed Services University
[4] Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of
来源：
Virologica Sinica | 2013年 / 28卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.
引用
收藏
页码：71 / 80
页数：10
相关论文
共 50 条
  • [21] Characterization and epitope mapping of a panel of monoclonal antibodies against HIV-1 matrix protein
    Zhang, Zhiqing
    Zhang, Feng
    Bai, Shimeng
    Qiao, Jiaming
    Shen, Honglin
    Huang, Fang
    Gao, Shuangquan
    Li, Shaowei
    Gu, Ying
    Xia, Ningshao
    BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2018, 65 (06) : 807 - 815
  • [22] Isolation of neutralizing monoclonal antibodies against HIV-1 with predetermined conformational epitope specificity
    Sholukh, Anton
    Mukhtar, Muhammad
    Humbert, Michael
    Essono, Sosthene
    Watkins, Jennifer
    Shanmuganathan, Vivekanandan
    Hemashettar, Girish
    Hu, Shiu-Lok
    Montefiori, David
    Polonis, Victoria
    Schur, Peter
    Ruprecht, Ruth
    JOURNAL OF IMMUNOLOGY, 2012, 188
  • [23] Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors
    Chen, Weizao
    Dimitrov, Dimiter S.
    CURRENT OPINION IN HIV AND AIDS, 2009, 4 (02) : 112 - 117
  • [24] Potent monoclonal antibodies to control HIV-1 replication
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (03) : 221 - 221
  • [25] Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design
    Chen, Weizao
    Ying, Tianlei
    Dimitrov, Dimiter S.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (05) : 657 - 671
  • [26] Unleashing natural antibodies against HIV-1
    Ben-Shalom, Noam
    Freund, Natalia T.
    CELL HOST & MICROBE, 2021, 29 (06) : 849 - 851
  • [27] Monoclonal antibodies as therapeutics in human malignancies
    Pandey, Manjari
    Mahadevan, Daruka
    FUTURE ONCOLOGY, 2014, 10 (04) : 609 - 636
  • [28] ANALYSIS OF COMMON EPITOPES ON GAG PROTEINS OF HIV-1, HIV-2 AND SIV[AGM] USING MONOCLONAL-ANTIBODIES AGAINST HIV-1
    ASANO, M
    MORIKAWA, S
    TATSUMI, M
    SHIMIZU, H
    USHIJIMA, H
    KITAMURA, T
    JAPANESE JOURNAL OF MEDICAL SCIENCE & BIOLOGY, 1991, 44 (02): : 41 - 49
  • [29] Monoclonal antibodies against topoisomerase I suppressed DNA relaxation and HIV-1 cDNA synthesis
    Takahashi, H
    Iwata, T
    Kitagawa, Y
    Shoya, Y
    Takahashi, RH
    Nagashima, K
    Kurata, T
    HYBRIDOMA, 2000, 19 (04): : 331 - 334
  • [30] Competitive study of monoclonal antibodies against the HIV-1 Gp41 core structure
    Usami, O
    Xiao, P
    Ling, H
    Hattori, T
    MICROBIOLOGY AND IMMUNOLOGY, 2006, 50 (02) : 131 - 134
12345